Julie M. Reed, the executive director of the Biosimilars Forum, explains what needs to be done to ensure progress on biosimilar legislation and lower drug prices.
Julie M. Reed, the executive director of the Biosimilars Forum, explains what needs to be done to ensure progress on biosimilar legislation and lower drug prices.
Transcript
Lowering drug prices seems to be the one issue Republicans and Democrats can agree on but efforts to do so, including ones that could increase biosimilar access, are often stalled. What needs to happen to get these policies implemented?
Reed: They need to be prioritized and we need action. When we have opposition against these bills, we hear from policymakers that they’re hearing the market’s working fine. That is, there's depth—several different lenses to look at how the market is doing. The market is working where there's robust competition and access because you're seeing that competition and access lower the prices and you're getting greater cost savings. That's the goal here.
Where the market is not working is if you don't have access or don't have robust coverage of multiple biosimilars; you are not seeing the robust pricing competition and cost savings. So, I think it's very important that when it has bipartisan support. We’re leaving cost savings on the table—and billions of dollars in cost savings. And I think we're not the only ones shouting this from the hilltops. Academics are shouting it, researchers are shouting it, legislators are shouting it, patient groups and providers are shouting, like, “Help us get access to biosimilars because we need to treat our patients and we need to have cost savings!” And so, we need action. We need the action, and I hope we see it.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.